Elastin Biosciences Announces Breakthrough Discovery in Elastin Restoration: Paving the Way for Treatment of Elastin-Deficiency Diseases
Longaevus Technologies, announces the spin-off of Elastin Biosciences following breakthrough preclinical results of 3 of its assets. Longaevus Technologies is a company builder with dedicated to longevity, with an all-round approach to reversing aging based on its multiple hallmarks. Longaevus Technologies combines the expertise of an international team of renowned scientists from major universities and organizations, academics and industry experts to reach the common goal of reversing aging.
After being in stealth mode for a year, Elastin Biosciences, an innovative biotech company spun off from Longaeuvus Technologies, has unveiled a groundbreaking discovery in the realm of elastin-related health. Elastin Biosciences, with its core team comprising Chief Scientist Alexey Moskalev, and Director of Research Alexander Fedintsev, CEO Sherif Idriss, has successfully performed experiments in Oxford and identified three novel drug combinations that inhibit elastin degradation and foster its deposition, leading to an increase in elastin expression by 5-fold, and improving aortic elasticity in aged mice in-vivo. Longaevus Technologies currently has 3 more companies in stealth mode.
This cutting-edge research promises to offer solutions for individuals affected by elastin-deficiency related diseases and also has the potential to significantly promote healthy longevity. Transitioning from preclinical proof of concept to the pre-IND phase, this development showcases the company's dedication and commitment to pioneering the future of regenerative medicine. In a testament to the importance and potential of this research, Elastin Biosciences has secured an initial funding of $2.5 million. Bolstered by this support, the company is also prepping to launch a Series A funding round to further its mission and research endeavors.
The degradation of elastin, linked with a variety of health issues as well as the natural aging process, has long been on the radar of medical experts. This breakthrough by Elastin Biosciences not only brings renewed hope for those directly afflicted by elastin-deficiency but also charts a path for innovative treatments designed to bolster overall health and longevity.
Elastin Biosciences is now poised to make significant strides in regenerative medicine, ushering in a new era of treatment solutions and healthy aging.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230831595786/en/
Contact information
Sherif Idriss
+4917632276520 / sherif@longaevus.tech
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 202525.7.2025 00:02:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present key data from its oncology portfolio at the upcoming European Society of Medical Oncology (ESMO) Congress 2025, to be held October 17-21 in Berlin. “We're looking forward to presenting the latest findings across our oncology portfolio at this year’s congress, including initial data for our TGFβR2×PD-1-directed bispecific antibody, INCA33890, and our novel, selective and orally bioavailable inhibitor of G12D-mutated KRAS, INCB161734,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data underscore the importance of establishing treatment options for advanced solid tumors and speak to the potential of INCA33890 and INCB161734 as personalized therapies to enhance outcomes for patients with cancer across a range of tumor types.” Details on the abstracts accepted for oral presentation at ESMO include: INCB161734 (KRAS G12D) Preliminary Phase 1 Results Of INCB161734, A Novel Oral K
DNIB.com Reports Internet Has 371.7 Million Domain Name Registrations at the End of the Second Quarter of 202525.7.2025 00:01:00 EEST | Press release
VeriSign, Inc. (NASDAQ: VRSN), a global provider of critical internet infrastructure and domain name registry services, today announced that, according to the latest Domain Name Industry Brief Quarterly Report from DNIB.com, the second quarter of 2025 closed with 371.7 million domain name registrations across all top-level domains (TLDs), an increase of 3.3 million domain name registrations, or 0.9% compared to the first quarter of 2025. Domain name registrations also increased by 9.3 million, or 2.6%, year over year. The .com and .net TLDs had a combined total of 170.5 million domain name registrations in the domain name base at the end of the second quarter of 2025, an increase of 0.7 million domain name registrations, or 0.4% compared to the first quarter of 2025. The .com and .net TLDs had a combined decrease of 0.1 million domain name registrations, or 0.1%, year over year. As of June 30, 2025, the .com domain name base totaled 157.9 million domain name registrations and the .net
SES and the Luxembourg Government to Develop and Launch New Defence Satellite for GovSat24.7.2025 19:55:00 EEST | Press release
SES and the Luxembourg Government today announced their plan for development of a second satellite for GovSat (LuxGovSat S.A.), the public-private partnership and 50/50 joint venture between SES and the Luxembourg Government that provides secure, reliable and accessible satellite communication services for governments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250724379713/en/ GovSat-2. Copyright: Thales Alenia Space GovSat-2 will be positioned over the European satellite arc. It will join GovSat-1 in augmenting reliable connectivity services for government customers over the region. The satellite will be built by Thales Alenia Space on its Spacebus 4000B2 platform. Since launching in 2018, the joint venture’s first defence satellite, GovSat-1, operated by GovSat from a secure missions operations centre in Luxembourg, has supported the Luxembourg Directorate of Defence, EU and NATO nations, the U.S. Department of Defens
Infobip Named a Leader in 2025 Gartner ® Magic Quadrant™ for Communications Platform-as-a-Service for the Third Consecutive Year24.7.2025 19:21:00 EEST | Press release
Global communications platformInfobiphas once again been named a Leader in the 2025 Gartner Magic Quadrant for Communications Platform-as-a-Service (CPaaS)1. This year the company is placed furthest in Completeness of Vision. Infobip views this third consecutive recognition as acknowledging its status as a global CPaaS powerhouse. Magic Quadrant2 reports are a culmination of rigorous, fact-based research in specific markets, providing a wide-angle view of the relative positions of the providers in markets where growth is high and provider differentiation is distinct. Providers are positioned into four quadrants: Leaders, Challengers, Visionaries and Niche Players. The research enables customers to get the most from market analysis in alignment with their unique business and technology needs. As a Leader, Infobip is recognized for both its Ability to Execute and its Completeness of Vision. Infobip powers conversations for some of the world’s most innovative businesses including Microsof
Andersen Consulting Expands AI and Digital Transformation Capabilities with Rysun24.7.2025 16:30:00 EEST | Press release
Andersen Consulting strengthens its AI and digital transformation capabilities with collaborating firm Rysun, a technology consultancy specializing in helping enterprises adopt AI and modernize core systems for agility and growth. Rysun helps enterprises scale generative AI initiatives through intelligent data platforms, modern digital foundations, and robust product engineering. With deep expertise in technology, retail, and energy, Rysun provides clients with solutions that drive innovation, efficiency, and customer engagement. “Our collaboration with Andersen Consulting helps us bring our vision of simplifying enterprise AI to a broader client base,” said Vishal Shukla, CEO of Rysun. “Together, we look forward to empowering organizations to maximize returns on their digital investments, scale AI with confidence, and adapt with agility and resilience in a rapidly evolving market.” “This collaboration advances our mission to help clients lead through digital disruption with the most i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom